In this episode, Sam Ulin, Debbie Zhuang, and Matthew Murphy dive into the strategic heart of biotech platform assessment. From evaluating technology differentiation to navigating investment shifts and manufacturing trends, the conversation is fast-paced, unscripted, and packed with insight.
By providing my email address, I agree to ClearView's online policies